highperformr logo

Kymera Therapeutics's Overview

Total employees243
HeadquartersWatertown
Founded2016

Kymera Therapeutics (NASDAQ: KYMR) is a clinical-stage biopharmaceutical company pioneering a new class of small molecule medicines called targeted protein degraders. Kymera is advancing its proprietary Pegasus™ platform, a drug discovery engine, to design and develop novel therapeutics that selectively degrade disease-causing proteins. Their focus areas include immunology-inflammation and oncology. Kymera aims to address previously undruggable targets and offer new treatment options for patients with serious diseases.

Where is Kymera Therapeutics's Headquarters?

HQ Function

The headquarters serves as the central hub for Kymera's research and development, corporate operations, clinical development, and strategic leadership.

Notable Features:

Located within Arsenal Yards, a modern mixed-use development, offering state-of-the-art laboratory and office spaces. The area is known for its vibrant atmosphere and accessibility.

Work Culture:

The work culture at Kymera is described as innovative, collaborative, science-driven, and patient-focused, with a strong emphasis on teamwork and scientific excellence to tackle challenging diseases.

HQ Significance:

Its location in the Boston-Cambridge biotech supercluster provides access to a rich talent pool, leading academic and research institutions, and a network of collaborators and service providers, crucial for a biopharmaceutical company.

Values Reflected in HQ: The choice of a modern, collaborative space in a redeveloped historic site reflects Kymera's values of innovation, progress, and building for the future while being part of a dynamic community.

Location:

Kymera Therapeutics is primarily based in the United States, with its research, development, and corporate operations centered at its Watertown, MA headquarters. While its physical office presence is U.S.-centric, its clinical trials are often conducted globally through partnerships with contract research organizations (CROs) to reach diverse patient populations. Future commercialization efforts for its drug candidates may also involve global partnerships or establishing international operations.

Street Address:

200 Arsenal Yards Blvd, Suite 230

City:

Watertown

State/Province:

MA

Country:

USA

Kymera Therapeutics's Global Presence

Buying Intent Signals for Kymera Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Kymera Therapeutics

As of April 2025, Kymera Therapeutics' leadership includes:

Nello Mainolfi, Ph.D. - Founder, President & Chief Executive Officer
Bruce Jacobs - Chief Financial Officer
Jared Gollob, M.D. - Chief Medical Officer
Joanna Brewer, Ph.D. - Chief Scientific Officer
Elaine Caughey, MBA - Chief Business Officer
Ellenāda Continuing - Chief Legal and Compliance Officer, Corporate Secretary
Sachin P. Fucci - Chief People Officer

Investors of Kymera Therapeutics

Kymera Therapeutics has been backed by several prominent investors over the years, including:

Atlas Venture
Lilly Ventures
Pfizer Ventures
Vertex Pharmaceuticals
Sanofi Ventures (formerly Sanofi-Genzyme BioVentures)
BVF Partners L.P.
Wellington Management
Rock Springs Capital
6 Dimensions Capital

Executive New Hires/Exits in the Last 12 Months

Hire0
Exits0

Kymera Therapeutics has maintained relative stability in its core C-suite leadership over the past 12 months, focusing on advancing its clinical pipeline. Any changes generally reflect strategic growth and strengthening of functional capabilities.

Technology (Tech Stack) used by Kymera Therapeutics

Discover the tools Kymera Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Kymera Therapeutics Email Formats and Examples

Kymera Therapeutics likely utilizes a common corporate email format, often combining elements of an employee's name with the company domain. A frequently observed pattern for companies of this nature is the first initial followed by the last name.

[first_initial][last]@kymeratx.com

Format

jdoe@kymeratx.com

Example

80%

Success rate

News and media

GlobeNewswire2024-06-03

Kymera Therapeutics Presents Updated Phase 1 Clinical Data for KT-253, a Novel MDM2 Degrader, at the 2024 ASCO Annual Meeting

Kymera Therapeutics presented updated data from its Phase 1 trial of KT-253 in patients with relapsed or refractory high-grade myeloid malignancies and solid tumors. The data showed KT-253's potential with robust p53 induction and evidence of clinical activity, including complete responses....more

GlobeNewswire2024-05-09

Kymera Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Program Progress

Kymera reported its Q1 2024 financial results, highlighting progress across its pipeline, including KT-474 (IRAK4 degrader) in hidradenitis suppurativa and atopic dermatitis, and oncology programs KT-333 (STAT3 degrader) and KT-253 (MDM2 degrader). The company emphasized its strong cash position to fund operations....more

GlobeNewswire2024-04-08

Kymera Therapeutics Presents New Preclinical Data Highlighting the Potential of STAT6 Degraders for the Treatment of Allergic Diseases

Kymera presented preclinical data on its STAT6 degrader program at the AACR Annual Meeting 2024, demonstrating potent and selective STAT6 degradation. These findings support the potential of STAT6 degraders as a novel therapeutic approach for a range of allergic and inflammatory diseases, including asthma and atopic dermatitis....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Kymera Therapeutics, are just a search away.